Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
Scientific presentation

Issues faced when using targeted NGS panels in the clinic for diagnosis, prognosis, and treatment


Alexander Perl, MD
Catherine Smith, MD

Description

Large cancer centers have adopted Next Generation Sequencing (NGS) in the clinic for diagnosis, prognosis, and treatment decisions. Dr. Catherine Smith, from UCSF, discusses the issues faced with targeted panels in the clinic and the differences between amplicon and hybridization methods. While Dr. Alexander Perl, from the University of Pennsylvania, discusses the findings in their collaborative CHRYSALIS study of the FLT3 inhibitor Gilteritinib in relapsed/refractory AML where they used quantifiable single-cell DNA analysis to enable dynamic therapy selection.



VIEW


Scientific presentation
CHIP’ing away at somatic mosaicism — Diving into the promises and challenges of characterizing clonal hematopoiesis of indeterminate potential
Ross Levine, MD
Kelly Bolton, MD, PhD
Jyoti Nangalia, MD, PhD
Todd Druley, MD, PhD
(2022)
Scientific presentation
Meet the Authors: Clonal Heterogeneity in Acute Lymphoblastic Leukemia at Diagnosis and During Chemo Treatment
Jan Cools, PhD, VIB Center for Cancer Biology
(2022)
Scientific presentation
AMP 2021 Corporate Workshop: Single-cell DNA and multi-omics strategies for untangling therapy-resistant mechanisms in oncology
John Lee, M.D., Ph.D., Fred Hutchinson Cancer Research Center & Julia Gouffon, Ph.D., Mission Bio
Association for Molecular Pathology 2021 Digital Experience (2021)
Scientific presentation
Do More Single Cell with Less – Tapestri Platform Expansion for Hematologic Malignancy Research
Koichi Takahashi, MD, PhD, MD Anderson Cancer Center & Jim Flynn, PhD, Mission Bio
(2021)
REQUEST QUOTE